vs

Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and SMITH MIDLAND CORP (SMID). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $23.1M, roughly 1.7× SMITH MIDLAND CORP). SMITH MIDLAND CORP runs the higher net margin — 9.2% vs -161.8%, a 171.0% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 24.7%).

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

Smith Midland Corp is a specialized manufacturer of precast concrete products for infrastructure, commercial, residential and industrial construction uses. Its key product lines include highway safety barriers, acoustic sound walls, architectural precast panels, and stormwater management systems, serving primarily the North American market with durable, sustainable construction solutions.

IBRX vs SMID — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.7× larger
IBRX
$38.3M
$23.1M
SMID
Growing faster (revenue YoY)
IBRX
IBRX
+382.2% gap
IBRX
407.0%
24.7%
SMID
Higher net margin
SMID
SMID
171.0% more per $
SMID
9.2%
-161.8%
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IBRX
IBRX
SMID
SMID
Revenue
$38.3M
$23.1M
Net Profit
$-61.9M
$2.1M
Gross Margin
99.0%
57.5%
Operating Margin
-169.0%
37.8%
Net Margin
-161.8%
9.2%
Revenue YoY
407.0%
24.7%
Net Profit YoY
-4.7%
52.5%
EPS (diluted)
$-0.06
$0.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IBRX
IBRX
SMID
SMID
Q4 25
$38.3M
$23.1M
Q3 25
$32.1M
$21.5M
Q2 25
$26.4M
$26.2M
Q1 25
$16.5M
$22.7M
Q4 24
$7.6M
$18.5M
Q3 24
$6.1M
$23.6M
Q2 24
$19.6M
Q1 24
$16.8M
Net Profit
IBRX
IBRX
SMID
SMID
Q4 25
$-61.9M
$2.1M
Q3 25
$-67.3M
$2.9M
Q2 25
$-92.6M
$4.2M
Q1 25
$-129.6M
$3.3M
Q4 24
$-59.2M
$1.4M
Q3 24
$-85.7M
$3.1M
Q2 24
$2.0M
Q1 24
$1.1M
Gross Margin
IBRX
IBRX
SMID
SMID
Q4 25
99.0%
57.5%
Q3 25
99.4%
26.8%
Q2 25
99.5%
0.0%
Q1 25
99.6%
30.7%
Q4 24
51.4%
Q3 24
27.9%
Q2 24
0.0%
Q1 24
23.3%
Operating Margin
IBRX
IBRX
SMID
SMID
Q4 25
-169.0%
37.8%
Q3 25
-173.5%
18.0%
Q2 25
-269.8%
0.0%
Q1 25
-390.1%
19.3%
Q4 24
-919.0%
24.5%
Q3 24
-1314.3%
16.3%
Q2 24
0.0%
Q1 24
9.0%
Net Margin
IBRX
IBRX
SMID
SMID
Q4 25
-161.8%
9.2%
Q3 25
-209.8%
13.4%
Q2 25
-350.3%
15.9%
Q1 25
-784.9%
14.7%
Q4 24
-783.4%
7.5%
Q3 24
-1404.0%
13.4%
Q2 24
10.1%
Q1 24
6.8%
EPS (diluted)
IBRX
IBRX
SMID
SMID
Q4 25
$-0.06
$0.41
Q3 25
$-0.07
$0.54
Q2 25
$-0.10
$0.79
Q1 25
$-0.15
$0.62
Q4 24
$-0.08
$0.28
Q3 24
$-0.14
$0.59
Q2 24
$0.37
Q1 24
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IBRX
IBRX
SMID
SMID
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$-500.5M
$54.3M
Total Assets
$501.9M
$87.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IBRX
IBRX
SMID
SMID
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Q1 24
Stockholders' Equity
IBRX
IBRX
SMID
SMID
Q4 25
$-500.5M
$54.3M
Q3 25
$-524.3M
$52.1M
Q2 25
$-570.7M
$49.2M
Q1 25
$-591.4M
$45.1M
Q4 24
$-489.1M
$41.7M
Q3 24
$-745.1M
$40.3M
Q2 24
$37.2M
Q1 24
$35.3M
Total Assets
IBRX
IBRX
SMID
SMID
Q4 25
$501.9M
$87.7M
Q3 25
$519.0M
$85.4M
Q2 25
$402.1M
$81.2K
Q1 25
$303.8M
$74.7M
Q4 24
$382.9M
$68.0M
Q3 24
$364.6M
$66.6M
Q2 24
$64.0M
Q1 24
$64.9M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IBRX
IBRX
SMID
SMID
Operating Cash FlowLast quarter
$-70.4M
Free Cash FlowOCF − Capex
$-71.3M
FCF MarginFCF / Revenue
-186.2%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IBRX
IBRX
SMID
SMID
Q4 25
$-70.4M
Q3 25
$-68.9M
$11.7M
Q2 25
$-79.7M
Q1 25
$-85.9M
$2.2M
Q4 24
$-85.1M
$-645.0K
Q3 24
$-98.8M
$3.9M
Q2 24
$2.7M
Q1 24
$-777.0K
Free Cash Flow
IBRX
IBRX
SMID
SMID
Q4 25
$-71.3M
Q3 25
$-69.6M
$6.3M
Q2 25
$-80.8M
Q1 25
$-87.0M
$1.6M
Q4 24
$-87.3M
$-1.3M
Q3 24
$-101.6M
$1.8M
Q2 24
$998.0K
Q1 24
$-2.6M
FCF Margin
IBRX
IBRX
SMID
SMID
Q4 25
-186.2%
Q3 25
-217.2%
29.5%
Q2 25
-305.9%
Q1 25
-526.9%
7.1%
Q4 24
-1155.4%
-7.0%
Q3 24
-1663.2%
7.8%
Q2 24
5.1%
Q1 24
-15.3%
Capex Intensity
IBRX
IBRX
SMID
SMID
Q4 25
2.4%
Q3 25
2.3%
25.1%
Q2 25
4.1%
Q1 25
6.8%
2.6%
Q4 24
28.0%
3.6%
Q3 24
45.7%
8.6%
Q2 24
8.7%
Q1 24
10.7%
Cash Conversion
IBRX
IBRX
SMID
SMID
Q4 25
Q3 25
4.07×
Q2 25
Q1 25
0.67×
Q4 24
-0.46×
Q3 24
1.23×
Q2 24
1.37×
Q1 24
-0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IBRX
IBRX

Segment breakdown not available.

SMID
SMID

Product Sales$13.8M60%
Service Revenue$9.3M40%

Related Comparisons